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Abstract 
Background: Cerebral ischemic stroke is a significant cause of morbidity and mortality. Sex differences exist follow-
ing stroke in terms of incidence, symptoms, outcomes and response to some treatments. Importantly, molecular 
mechanisms of injury, activated following ischemia may differ between the sexes and if so may account, at least 
in part, for sex differences seen in treatment response. Here we aimed to determine, using single-sex organotypic 
hippocampal slice cultures, whether the effectiveness of a potential treatment option, i.e. sex steroids, exhibited any 
sexual dimorphism and whether sex affected the mechanisms of apoptosis activated following ischemia.
Results: Following exposure to ischemia, male-derived tissue exhibited higher levels of cell death than female-
derived tissue. Various sex steroid hormones, i.e. progesterone, allopregnanolone, and estradiol, were protective 
in terms of reducing the amount of cell death in male- and female-derived tissue whereas medoxyprogesterone 
acetate (MPA) was only protective in female-derived tissue. The protective effect of progesterone was abolished in the 
presence of finasteride, a 5α-reductase inhibitor, suggesting it was largely mediated via its conversion to allopregna-
nolone. To test the hypothesis that sex differences exist in the activation of specific elements of the apoptotic path-
way activated following ischemia we administered Q-VD-OPH, a caspase inhibitor, or PJ34, an inhibitor of poly (ADP 
ribose) polymerase (PARP). Caspase inhibition was only effective, in terms of reducing cell death, in female-derived tis-
sue, whereas PARP inhibition was only protective in male-derived tissue. However, in both sexes, the protective effects 
of progesterone and estradiol were not observed in the presence of either caspase or PARP inhibition.
Conclusions: Sex differences exist in both the amount of cell death produced and those elements of the cell death 
pathway activated following an ischemic insult. There are also some sex differences in the effectiveness of steroid hor-
mones to provide neuroprotection following an ischemic insult—namely MPA was only protective in female-derived 
tissue. This adds further support to the notion sex is an important factor to consider when investigating future drug 
targets for CNS disorders, such as ischemic stroke.
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Background
Cerebral ischemic stroke is a major cause of mortality 
and morbidity with limited effective treatments available 
[1]. Multiple factors influence both the incidence and 
outcome of ischemic stroke including sex, age, race/eth-
nicity, hypertension, cardiac disease, diabetes mellitus, 
hypercholesterolemia, cigarette smoking and alcohol 
abuse [2]. Sex differences are reported to occur in the 
causes, symptoms and outcomes following stroke [3]. 
For example, over the lifespan, women have a higher risk 
of stroke and increased rates of post-stroke mortality, 
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disability, depression and dementia, compared to men 
[4]. Such an increased risk and worsened post-stroke 
seen in women may be a consequence of women’s longer 
life expectancy due to age being the strongest independ-
ent risk factor for stroke [5] and a negative predictor for 
clinical outcome [6]. However, a significant reduction in 
the occurrence of stroke and a relatively better outcome 
following stroke occurs in pre-menopausal women com-
pared to men of the same age [7]. During the menopausal 
period, females experience a rapid increase in the inci-
dence of stroke compared to males, which is coincident 
with decreasing levels of the circulating sex hormones, 
i.e. oestrogens and progesterone [8]. Steroid hormones 
have been investigated, and demonstrated to be protec-
tive, following ischemic stroke using both in  vitro and 
in  vivo models [9–12]. However, sex differences may 
occur in response to treatment, such as steroid hor-
mones, which has been reported previously for aspi-
rin, warfarin and thrombolytic therapy following stroke 
[13–15].
Ischemic stroke initiates a complex pathology includ-
ing excitotoxicity, cell necrosis, apoptosis, inflammation, 
increased oxidative stress and breakdown of the blood 
brain barrier along with the potential for reperfusion 
injury [16]. Sex-specific cultures, derived from neonatal 
populations, demonstrate that female-derived cells are 
more resistant to ischemic stroke than male-derived cells 
and following ischemic injury several molecular mecha-
nisms of the injury mechanisms, such as inflammation, 
cell death, oxidative stress, and microglial activation 
may function dimorphically [17–19]. The mechanisms of 
injury following stroke may be affected by sex either as a 
consequence of intrinsic, i.e. chromosomal, or hormonal 
differences between the sexes. Sex differences in cerebral 
ischemia are reported in studies using both neonatal and 
adult animals suggesting that primary sex hormones are 
not the only factor influencing sex-influenced neuronal 
injury [20]. It is likely that sexual dimorphisms become 
established during development, when hormone lev-
els are low, as a result of variations in cell signalling and 
response to ischemia [21].
There are important differences between the sexes in 
the cell death pathways activated following ischemia. For 
example, it has been demonstrated that female-derived 
tissue is more sensitive to caspase-mediated cell death, 
whereas cell death in male-derived tissue is more likely to 
be triggered by caspase-independent pathways involving 
the activation of poly (ADP ribose) polymerase (PARP) 
and the translocation of apoptosis-inducing factor (AIF) 
[22–24]. Our aim here is twofold—firstly we aim to deter-
mine if sex-specific effects occur in the protectiveness of 
steroid hormones under ischemic conditions and sec-
ondly to investigate whether sex affects the mechanisms 
of cell death activated following ischemia. Improving 
our understanding of the mechanisms that may underlie 
sex differences, both in terms of responsiveness to treat-
ment and activated injury mechanisms, may lead to new 
individualised treatment strategies for disorders such as 
ischemic stroke.
Results
Following oxygen and glucose deprivation (OGD) there 
was a significant increase in the amount of cell death in 
both CA1 and dentate gyrus (DG) regions within the 
neonatal hippocampal slice cultures which was seen 
in both male (P < 0.001) and female-derived (P < 0.001) 
slices compared to normoxic controls. Figure  1a shows 
representative images from the CA1 region of Hoechst 
and propidium iodide labelled cells for male and female-
derived cultures exposed to normoxia and 4 h of OGD. 
There was a significantly increased amount of cell death 
in male-derived compared to female-derived slices in 
the CA1 (45.36 ± 2.34% vs. 27.36 ± 2.10% P < 0.001) and 
DG (27.25 ± 1.46% vs. 16.13 ± 1.38% P < 0.001) regions 
(Fig. 1b).
We then determined whether the effect of the various 
vehicle treatments (i.e. dimethyl sulfoxide, DMSO; dis-
tilled water) had any effect on the amount of cell death 
seen in the CA1 and DG regions (Fig. 2). In male-derived 
cells there was an increase in the amount of cell death 
following exposure to OGD and distilled water in com-
parison to OGD only or OGD and DMSO in the CA1 
(P < 0.05) and dentate gyrus (P < 0.01) regions. In female-
derived slices, the addition of either DMSO or distilled 
water had no effect on the amount of cell death in com-
parison to OGD only.
In order to determine the sex-specific effects of vari-
ous steroid hormones on the amount of cell death fol-
lowing OGD we exposed cultures to progesterone, 
allopregnanolone, medoxyprogesterone or estradiol at 
various concentrations. Following treatment with proges-
terone, a one-way ANOVA revealed a significant reduc-
tion in the amount of cell death in male-derived slices in 
the CA1  (F5,40 = 47.68, P < 0.001) and DG  (F5,40 = 58.78, 
P < 0.001) regions and in female-derived slices in the 
CA1  (F5,40 = 44.55, P < 0.001) and DG  (F5,40 = 28.34, 
P < 0.001) regions (Fig.  3a, b). Post-hoc tests showed 
that progesterone significantly (P < 0.001) reduced cell 
death at all concentrations tested, apart from 10  µm in 
female-derived slices and 10  µm in the CA1 region in 
male-derived slices. Allopregnanolone treatment, ana-
lysed via one-way ANOVA, revealed a significant reduc-
tion in the amount of cell death in both the CA1 and 
DG regions in both male (CA1  F4,32 = 21.23, P < 0.001; 
DG  F4,32 = 18.98, P < 0.001) and female-derived (CA1 
 F4,32 = 14.80, P < 0.001; DG  F4,32 = 15.50, P < 0.001) slices 
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(Fig.  3c, d). Post-hoc tests showed that allopregna-
nolone significantly (P < 0.001) reduced cell death at 0.1 
and 1.0 µm in the CA1 region in both male and female-
derived cells. Within the DG region, allopregnanolone 
significantly reduced the amount of cell death at all 
concentrations tested in male-derived slices but was only 
effective at 0.1  µm in females. There was no significant 
effect of MPA treatment in male-derived cells in either 
the CA1 (P = 0.95) or DG (P = 0.85) regions. In female-
derived slices, MPA did significantly reduce the amount 
Fig. 1 Representative images of hippocampal CA1 slices exposed to normoxic and OGD conditions from male and female animals (a). All cell 
nuclei are shown by Hoechst staining and cell death is shown in images stained with PI (a). Cell death was analysed for both the CA1 and dentate 
gyrus (DG) regions and was found to be significantly increased following exposure to OGD (b, *P < 0.001 vs. normoxic control). In addition, following 
OGD, the amount of cell death seen in male-derived slices was significantly increased compared to female animals in both CA1 and DG regions (# 
P < 0.001). Data are expressed as mean ± SEM and n = 8 independent wells. Scale bars represent 20 µm
Fig. 2 Cell death was analysed in both the CA1 and dentate gyrus (DG) regions following OGD and inclusion of DMSO or distilled water (DW). In 
male-derived cultures, there was a significant increase in the amount of cell death, in both regions, following inclusion of DW (*P < 0.05 vs. OGD 
only; #P < 0.05 vs. OGD + DMSO). In female-derived cultures there was no significant differences in the amount of cell death between the treatment 
conditions. Data are expressed as mean ± SEM and n = 8–18 independent wells
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Fig. 3 Cell death was analysed in both the CA1 and DG regions following OGD and exposure to varying concentrations of progesterone (PROG; a, 
b), allopregnanolone (ALLO; c, d), medroxyprogesterone acetate (MPA; e, f) and estradiol (E2; g, h). Data are shown separately for male (a, c, e, g) and 
female-derived (b, d, f, h) cultures. Significant (P < 0.05) reductions in the amount of cell death following hormone treatment compared to DMSO 
are indicated by *. Data are expressed as mean ± SEM and n = 8 independent wells
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of cell death in the CA1  (F4,32 = 64.12, P < 0.001) and DG 
 (F4,32 = 39.10, P < 0.001) regions (Fig.  3e, f ). Post-hoc 
tests showed that, in female-derived slices, cell death 
was only significantly reduced (P < 0.001) in the pres-
ence of 10  µm MPA in both CA1 and DG regions. Fol-
lowing estradiol treatment, a one-way ANOVA revealed 
a significant reduction in the amount of cell death in both 
the CA1 and DG regions in both male (CA1  F4,32 = 55.98, 
P < 0.001; DG  F4,32 = 92.40, P < 0.001) and female-derived 
(CA1  F4,32 = 83.22, P < 0.001; DG  F4,32 = 46.11 P < 0.001) 
slices (Fig.  3g, h). Post-hoc tests showed that estradiol 
significantly (P < 0.05) reduced cell death at all concentra-
tions tested.
In order to test the hypothesis that progesterone is 
neuroprotective via its conversion to the active metabo-
lite allopregnanolone we applied progesterone, at a dose 
reported above to be protective, in conjunction with 
10  µm finasteride. Finasteride, a 5α-reductase inhibitor, 
prevents the conversion of progesterone to allopregna-
nolone. A one-way ANOVA revealed, that in both male 
and female-derived slices, there was no significant change 
in the amount of cell death seen in the CA1 (males, 
P = 0.09; females, P = 0.05) and DG (males, P = 0.14; 
females, P = 0.71) regions in the presence of finasteride 
or finasteride in combination with 0.1  µm progesterone 
in comparison to DMSO-only (Fig. 4). Thus, finasteride-
only did not affect the amount of cell death and the 
protective effect we had seen previously with 0.1 µm pro-
gesterone was absent in the presence of finasteride.
We went on to determine if there were any sex-specific 
effects in the efficacy of inhibitors of caspase (i.e. QJ-
VD-OPH) and PARP (i.e. PJ-34) activity at reducing cell 
death. Following treatment with QJ-VD-OPH, a one-way 
ANOVA revealed no significant difference in the amount 
of cell death in both the CA1 (P = 0.83) and DG (P = 0.8) 
regions in male-derived slices (Fig. 5a). In female-derived 
slices, a one-way ANOVA revealed that treatment with 
QJ-VD-OPH significantly reduced the amount of cell 
death in both the CA1  (F4,32 = 49.8, P < 0.001) and DG 
 (F4,32 = 46.58, P < 0.001) regions (Fig.  5b). Post-hoc tests 
showed that, in female-derived slices, QJ-VD-OPH sig-
nificantly (P < 0.01) reduced cell death at all concentra-
tions tested. Following treatment with PJ-32, a one-way 
ANOVA revealed a significant reduction in the amount 
of cell death in both the CA1  (F4,32 = 37.73, P < 0.001) and 
DG  (F4,32 = 47.31, P < 0.001) regions in male-derived slices 
(Fig.  5c). Post-hoc tests showed that, in male-derived 
slices, PJ-32 significantly (P < 0.05) reduced cell death at 
all concentrations tested. In female-derived slices, a one-
way ANOVA revealed that treatment with PJ-32 had no 
significant effect on the amount of cell death in the CA1 
(P = 0.39) and DG (P = 0.41) regions (Fig. 5d).
Finally, we aimed to determine if the protection seen 
with progesterone and estradiol was still present in 
the presence of inhibitors of specific elements of the 
apoptotic pathways. We tested progesterone and estra-
diol in the presence or absence of a caspase inhibitor, 
Q-VD-OPH, or a PARP inhibitor, PJ-34. The addition 
Fig. 4 Cell death was analysed in both the CA1 and DG regions following OGD and exposure to finasteride (FI) or FIe and progesterone. Finasteride 
did not affect the amount of cell death in female and male-derived cultures. The presence of FI with progesterone prevented the reduction in cell 
death seen with progesterone only treatment (*P < 0.05 vs. DMSO). Data are expressed as mean ± SEM and n = 8 independent wells
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of Q-VD-OPH, in both male and female-derived slices, 
to progesterone or estradiol at a concentration pre-
viously shown above to be protective, significantly 
(P < 0.001) increased the amount of cell death in com-
parison to progesterone- or estradiol-only in both CA1 
and DG regions (Fig. 6). Likewise, the addition of PJ-34, 
in both male and female-derived slices, to progester-
one or estradiol at a concentration previously shown 
(see above) to be protective significantly (P < 0.001) 
increased the amount of cell death in comparison to 
progesterone- or estradiol-only in both CA1 and DG 
regions (Fig.  6). Thus, suggesting that part of the pro-
tective effects of progesterone and estradiol were lost in 
the presence of either a caspase inhibitor, Q-VD-OPH, 
or a PARP inhibitor, PJ-34, in both sexes.
Discussion
The aim of this study was to determine if sexual dimor-
phism occurs in the protective effects of steroid hor-
mones and the mechanisms of cell death activated 
following ischemia. We observed that progesterone, 
allopregnanolone and estradiol were protective in terms 
of reducing the amount of cell death in both male- and 
female-derived tissue whereas medoxyprogesterone 
acetate was only protective in female-derived tissue. We 
also showed that caspase inhibition reduced cell death in 
Fig. 5 The addition of Q-VD-OPH did not affect the amount of cell death seen in male-derived slices (a). Exposure to Q-VD-OPH, at all 
concentrations tested, significantly reduced the amount of cell death in CA1 and DG regions compared to DMSO under OGD conditions in 
female-derived slices only (b, *P < 0.05 vs. DMSO). Exposure to PJ-34 did not affect the amount of cell death seen in female-derived slices (c). 
Treatment with PJ-34, at all concentrations tested, significantly reduced the amount of cell death in CA1 and DG regions compared to distilled water 
(DW) in male-derived slices only (d, *P < 0.05 vs. DW). Data are expressed as mean ± SEM and n = 8 independent wells
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female-derived tissue whereas PARP inhibition reduced 
cell death in male-derived tissue revealing differences 
between the sexes in the importance and contribution of 
various elements of the cell death pathways to the dam-
age produced following an ischemic insult.
Here we utilised a sex-specific in  vitro model of cell 
death which allows sex differences to be investigated 
in terms of responsiveness to CNS injury and treat-
ments. It is becoming increasingly clear that sex differ-
ences occur in terms of the incidence, pathology and 
response to treatment for a number of CNS disorders 
[25]. In terms of ischemia, although in vivo models may 
be more representative of human stroke, in vitro models 
do offer certain advantages as they allow investigation 
of both treatment effects and pathological mechanisms 
under a controlled environment avoiding possible con-
founding effects of temperature and vascular compo-
nents [26]. In vitro models generally use neonatal tissue 
and therefore may be of limited relevance to the adult-
ageing brain, in which stroke is more prevalent. Although 
data from preclinical studies and pediatric populations 
do demonstrate that sex differences do exist within the 
developing brain in the response to stroke [27]. The use 
of sex-typed cells, as described here, means that any 
Fig. 6 The presence of Q-VD-OPH, in both male and female-derived slices, in combination with either progesterone or estradiol significantly 
increased (*P < 0.01) the amount of cell death seen in comparison to progesterone or estradiol only in both CA1 and DG regions (a, b). The addition 
of PJ-34, in both male and female-derived slices, in combination with either progesterone or estradiol significantly increased (*P < 0.01) the amount 
of cell death seen in comparison to progesterone or estradiol only in both CA1 and DG regions (c, d). PROG: progesterone, E2: estradiol; data are 
expressed as mean ± SEM and n = 8 independent wells
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difference in outcome observed i.e. cell death, occurs 
as a consequence of inherent sex differences within the 
cells, from prenatal hormone exposure, or a combination 
of the two. However, neonatal and pre-adolescent cell 
populations have limited exposure to circulating sex ster-
oid hormones thus observed sex differences are probably 
independent of hormonal activational effects. In our cell 
populations, any differences between the sexes are prob-
ably accounted for by intrinsic sex differences related to 
the sex chromosomes rather than organizational effects 
of prenatal sex hormone exposure. Here we confirmed 
that sex differences occurred in the amount of cell death 
following OGD with male-derived cells being more sen-
sitive to OGD-induced cell death than female-derived 
cells. This is consistent with clinical and in  vivo studies 
which show, for example, that younger female rodents are 
more resistant to ischemic brain damages than younger 
male rodents [28].
In terms of steroid hormones, progesterone, allo-
pregnanolone and estradiol were protective, in terms 
of reducing the amount of cell death, in tissue derived 
from both sexes. Previous in  vitro and in  vivo studies 
have reported the protective effects of progesterone 
and estradiol but it is interesting here to determine 
their sex-specific effects. Progesterone and its active 
metabolite, allopregnanolone, are reported to be neu-
roprotective via a variety of mechanisms [29]. To test 
the hypothesis that progesterones effects are largely 
conveyed via its conversion to allopregnanolone we 
applied it in the presence of a 5α-reductase inhibi-
tor, finasteride, which prevented the protective effects 
of progesterone. Thus, in this experimental set up it 
would appear that progesterones protective effects are 
mediated via conversion to an active metabolite, such 
as allopregnanolone. However, progesterone is firstly 
converted to 5α-dihydroprogesterone (DHP) and then 
allopregnanolone and these conversions are catalysed 
by 5α-reductase and 3α-hydroxysteroid dehydrogenase 
enzymes, respectively. The metabolites may have differ-
ing effects under ischemic conditions as, for example, 
DHP, like progesterone, is able to act at the proges-
terone receptor whereas allopregnanolone acts at the 
GABA-A receptor. Finasteride inhibits the synthesis of 
5α-reduced neurosteroids and previous in  vitro stud-
ies using mixed cell cultures have reported inhibition 
of progesterone protection in the presence of finas-
teride [30, 31]. However, it may be worthy to investi-
gate other metabolites of progesterone as they have 
been shown to play a role in the protective properties 
of endogenous progesterone following experimental 
stroke [32]. MPA, is a synthetic progestin used com-
monly as part of hormonal replacement therapy or the 
contraceptive pill. In this study, MPA was found to be 
protective in female-derived tissue but had no effect in 
males whereas others have suggested that MPA is not 
able to provide protection of CNS tissue when utilising 
mixed cell cultures [33]. Sex differences in the protec-
tive effects of MPA may be due to its ability to bind not 
only to the classical progesterone receptor but also has 
have stimulator or inhibitory actions at glucocorticoid, 
androgenic or mineralocorticoid receptors which have 
shown to differ in their expression between the sexes 
[34].
We provide further evidence here that different ele-
ments of the cell death pathway, activated under ischemic 
conditions, differ between the sexes. The pan caspase 
inhibitor, Q-VD-OPH, used in this study was only pro-
tective in female-derived tissue which is similar to results 
reported for another pan caspase inhibitor i.e. z-VADfmk 
[22]. Application of PJ34 to inhibit PARP was only pro-
tective in male-derived tissue which has been reported 
in  vivo previously [35]. Thus, this study adds further 
evidence that male-derived tissue is more sensitive to 
caspase-independent cell death whereas female-derived 
tissue is more sensitive to caspase-dependent cell death. 
This has important implications for the design of appro-
priate treatments following ischemic stroke in terms of 
applicability to both sexes [36, 37]. However, as the neu-
roprotective effects of progesterone and estradiol were 
maintained in the presence of either a caspase or PARP 
inhibitor this would suggest that activation of either of 
these is not critical for the protective effects of progester-
one or estradiol.
Conclusions
Sex differences exist in both the amount of cell death 
produced and those elements of the cell death pathway 
activated following an ischemic insult. There are also 
some sex differences in the effectiveness of steroid hor-
mones to provide neuroprotection following an ischemic 
insult. Thus, there is increasing evidence that sex must be 
taken into account when investigating future drug targets 
for CNS disorders, such as ischemic stroke.
Methods
Animals
In vitro cultures were prepared, as previously described 
[38, 39], from 4–9 days old mouse C57/Bl6 pups housed 
in a specific pathogen free (SPF) unit with ad  libitum 
access to food and water. Animals, typically weighing 
less than 10  g, were euthanised using humane cervi-
cal dislocation under UK Home Office regulations. The 
animal welfare and ethics committee of the University 
of Leicester approved all experimental protocols. All 
animals were supplied by Charles River UK. Sex of the 
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pups was determined by visible inspection of anogen-
ital distance as female mice have a genital area much 
closer to the anus compared to male mice. Also, pig-
mented cells on the scrotum are visible to the naked eye 
on the day of birth in male mice compared to female 
mice in C57/Bl6 pups and female mice have 10 nipples 
compared to male mice that do not have nipples [40].
In vitro ischemia
Organotypic hippocampal cultures (OHSCs) were pre-
pared according to the methods of Stoppini et  al. [41] 
with some modifications, as we have reported previ-
ously [38, 39]. Briefly, brains were removed from the 
animals and the hippocampi dissected. The hippocampi 
were then sliced at 350  µm using a McIlwain tissue 
chopper and prepared in ice-cold dissecting medium 
containing HBSS (Hanks Balanced Salt Solution), 
4.5  mg/ml glucose solution and 3.75  µg/ml ampho-
tericin B. The slices were separated and placed onto 
Millicell membrane inserts (0.4  µm, Millipore) in six 
well plates, and cultured in growth medium contain-
ing 50% MEM (minimal essential medium), 25% horse 
serum, 25% HBSS, 0.5  mM glutamine, 4.5  mg/ml glu-
cose and 3.75  µg/ml amphotericin B. Cultures were 
maintained in a humidified incubator with 5%  CO2 at 
37  °C for 14  days and culture medium was changed 
every 3  days. All substances used for preparation and 
maintenance of cultures were obtained from Sigma 
unless stated.
OHSCs were exposed to OGD at day 14 by placing in 
OGD medium containing 75% MEM, 25% HBSS, 1 mM 
glutamine and 3.75  µg/ml amphotericin B which was 
bubbled for 30 min with 5%  CO2 and 95%  N2. After two 
washes with the OGD medium, 1  ml of OGD medium 
was placed in the well and plates were transferred to an 
anoxic chamber. The chamber was sealed and pumped 
with 5%  CO2 and 95%  N2 for 10 min then placed in an 
incubator at 37 °C for 4 h (OGD duration). The cultures 
were returned to oxygenated serum-free culture medium 
and placed back in the incubator for a further 24 h.
Drug treatments
Following OGD exposure, the cultures were returned to 
oxygenated serum-free culture medium containing one 
of the following treatments for a further 24  h: culture 
medium only, DMSO only, distilled water (DW) only, 
progesterone (0.01, 1.0 and 10 µm in DMSO), allopreg-
nanolone (0.1, 1.0 and 10  µm in DMSO), medroxy-
progesterone acetate (0.1, 1.0 and 10  µm in DMSO), 
17β-estradiol (0.1, 1.0 and 10 µm in DMSO), finasteride 
(10  µm in DMSO ± 0.1  µm progesterone), Q-VD-OPh 
(1, 5 and 10 µm in DMSO), or PJ-34 (0.1, 1.0 and 10 µm 
in DW).
Assessing cell death
To allow quantification of cell death, 30 min before the 
termination of experiments, the fluorescent cell death 
marker propidium iodide (PI, 5  µg/ml) and Hoechst 
(5  µg/ml) were added to the medium. At the termina-
tion of experiments, slices were fixed with 4% para-
formaldehyde at 4  °C for 2  h and then briefly washed 
in Phosphate Buffered Saline, removed from the mem-
brane inserts, mounted onto glass slides in PBS and 
imaged using a Nikon epifluorescence microscope. As 
previously described [38, 39] for each hippocampal 
slice, images were taken, using a Nikon microscope, 
from two different regions (CA1 and DG). For each 
region, two photos were taken, one image showing PI-
labelled cells and the other showing Hoescht-labelled 
nuclei. The number of cells in each image was counted 
manually by an individual blinded to the experimental 
condition. The percentage cell death was calculated by 
dividing the number of dying cells, as indicated by PI-
labelling, by the total number of cell nuclei, as indicated 
by Hoescht immunoreactivity.
Data analysis
Data are reported as means ± standard error of the 
mean (SEM) and data were normally distributed, as 
tested using the D’Agostino and Pearson normality 
test. Statistical significance between two conditions 
(e.g. normoxia vs. OGD, males vs. females) was deter-
mined using Student’s t-test, whereas, for comparison 
between more than two conditions (e.g. drug concen-
trations), statistical significance was calculated using 
one-way analysis of variance (ANOVA) followed by 
Tukey’s post hoc tests. The data were analysed using 
Graph Pad Prism Version 8.0 for Windows and the cri-
terion for statistical significance is P < 0.05. Slice cul-
tures were prepared from 2–4 pups (of each sex) and n 
is equal to the number of independent wells with each 
well having three slices.
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